COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Company Information
About this company
Key people
Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Michel Regnier
Senior Vice President, Chief Technology Officer
Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Anthony J. Giovinazzo
Director
Ulrich Kosciessa
Director
Ronald W. Miller
Director
Robert A. Seager
Director
David Spear
Director
Click to see more
Key facts
- Shares in issue3.18m
- EPICCSCI
- ISINCA22112H1010
- LocationCanada
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capCA$9.20m
- Employees21
- ExchangeToronto Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.